Study wrapper · #333
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Editor's note
This is a critical re-examination of bremelanotide's own pivotal evidence, and it is one of the most important items in this set for weighting the peptide. The authors scrutinize the efficacy measures from the Phase III RECONNECT trials and argue the primary instruments (the Female Sexual Function Index and its desire domain, and the FSDS-DAO distress scale) have, at best, questionable validity in women with HSDD. More pointedly, they report that 8 of 11 pre-registered clinicaltrials.gov efficacy outcomes had gone unpublished, and when they analyzed those, effect sizes ranged from nil to small, with several apparent benefits likely derived post-hoc. This is a methodological critique, not a new trial, and it does not allege the drug is harmful — but it directly challenges how impressive the approval-supporting results really are. Read alongside the trials themselves, it argues that bremelanotide's benefit is statistically modest and rests on outcome measures whose meaningfulness for these patients is unproven. It should meaningfully temper any strong efficacy reading.
Plain-language abstract
When a drug is approved, the results depend on the measuring tools used in its trials being trustworthy. This analysis takes a hard look at those tools for bremelanotide, using data from its main Phase III trials (called RECONNECT) in women with low sexual desire. The authors argue that the questionnaires used to judge whether the drug worked — measures of sexual function, desire, and distress — have weak evidence that they truly capture what matters for these women. They also point out a transparency problem: of 11 outcomes the trials had publicly promised to report, 8 had never been published. When the authors analyzed those missing outcomes themselves, the drug's effects ranged from none to small, and several of the more favorable-looking results appeared to have been calculated after the fact rather than planned in advance. Their overall conclusion is that bremelanotide's measured benefits are statistically modest and rest on outcome measures of uncertain meaning for women with this condition. This is a critical re-analysis of existing trial data, not a new study of patients, and it raises questions about how strong the original evidence really is.